Madhu Kalyan Pendurthi, MD
Pulmonary Disease · Springfield, MONPI 1750661286
Payments from drug & device makers
What this record shows
This record is dominated by education: $4,000 of the $6,413 with a category attached, or 62.4%. Intuitive Surgical accounts for 81.6% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2024 at $5,639 and has fallen 94.7% since, to $301 in 2025.
Across 40 payments — averaging $160.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$5K
- Merit Medical Systems Inc$353
- Inari Medical, Inc.$216
- United Therapeutics Corporation$135
- Actelion Pharmaceuticals US, Inc.$124
- Merck$89
- plus $263 from 8 others
Across 268 payments — averaging $1730.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Stryker$340K
- Inari Medical, Inc.$63K
- Kiniksa Pharmaceuticals, Ltd.$39K
- Boehringer Ingelheim$21K
What the payments were for
- Travel & lodging$1,11017%
- Food & beverage$1,30320%
- Education$4,00062%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 13 | $5,232 |
| Merit Medical Systems Inc | 2 | $353 |
| Inari Medical, Inc. | 2 | $216 |
| United Therapeutics Corporation | 3 | $135 |
| Actelion Pharmaceuticals US, Inc. | 2 | $124 |
| Merck | 4 | $89 |
| Boehringer Ingelheim | 3 | $69 |
| GSK | 3 | $54 |
| AstraZeneca | 3 | $50 |
| Grifols USA, LLC | 1 | $24 |
| Viatris Specialty LLC | 1 | $20 |
| Pulmonx Corporation | 1 | $16 |
| Johnson & Johnson | 1 | $16 |
| Insmed, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,413 in reported general payments places this provider in the 70th percentile of 295 pulmonary disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 56 | $712,613 |
| OfevNintedanib Esylate | 48 | $589,671 |
| UptraviSelexipag | 19 | $342,012 |
| Ambrisentan | 107 | $327,300 |
| Orenitram ErTreprostinil Diolamine | 27 | $211,877 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 13 | $155,131 |
| LetairisAmbrisentan | 13 | $150,723 |
| AdempasRiociguat | 11 | $149,078 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 147 | $106,751 |
| AdcircaTadalafil | 15 | $75,423 |
| Tadalafil | 24 | $35,731 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 39 | $30,982 |
| Sildenafil Citrate | 45 | $16,652 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 23 | $14,685 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 21 | $14,512 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $124 | $1,054,62575 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $69 | $611,23984 claims |
| Grifols USA, LLCProlastin C | $24 | $155,13113 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta | $54 | $128,574189 claims |
| United Therapeutics CorporationAdcirca | $135 | $75,42315 claims |
| AstraZenecaBreztri Aerosphere | $50 | $30,98239 claims |
| Johnson & JohnsonXarelto | $16 | $6,69512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 295 pulmonary disease providers in Missouri.
Other pulmonary disease in Springfield
- Mitchell AhrensSpringfield$12K
- Amy Ford TurnerSpringfield$12K
- Humam FarahHannibal$840K
- Derek ByersSaint Louis$835K
- Alexander ChenSaint Louis$679K
- Joseph OjileSaint Louis$538K
- Munaf SiyamwalaIndependence$413K
- Edward CharbekSaint Louis$372K
- Adeel KhanWashington$316K
- Marin KollefSaint Louis$264K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.